PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model

[1] Maccio A(2009)Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives [J] Obes Rev 10 660-670

[2] Madeddu C(2015)Global cancer statistics, 2012[J] CA Cancer J Clin 65 87-108

[3] Mantovani G(2016)Immune checkpoint inhibitors: therapeutic tools for breast Cancer[J] Asian Pac J Cancer Prev 17 905-910

[4] Torre LA(2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J] N Engl J Med 366 2455-2465

[5] Bray F(2010)Improved survival with ipilimumab in patients with metastatic melanoma[J] N Engl J Med 363 711-723

[6] Siegel RL(2016)Checkpoint inhibitors and their application in breast Cancer[J] Breast Care (Basel) 11 108-115

[7] Su M(2016)Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond[J] Ther Adv Med Oncol 8 360-374

[8] Huang CX(2016)Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC[J] Cancer Discov 6 F3-344

[9] Dai AP(2017)Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma[J] J Cancer 8 332-11446

[10] Brahmer JR(2007)Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation[J] Cancer Res 67 11438-120

[1] Maccio A(2009)Adipose tissue as target organ in the treatment of hormone-dependent breast cancer: new therapeutic perspectives [J] Obes Rev 10 660-670

[2] Madeddu C(2015)Global cancer statistics, 2012[J] CA Cancer J Clin 65 87-108

[3] Mantovani G(2016)Immune checkpoint inhibitors: therapeutic tools for breast Cancer[J] Asian Pac J Cancer Prev 17 905-910

[4] Torre LA(2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J] N Engl J Med 366 2455-2465

[5] Bray F(2010)Improved survival with ipilimumab in patients with metastatic melanoma[J] N Engl J Med 363 711-723

[6] Siegel RL(2016)Checkpoint inhibitors and their application in breast Cancer[J] Breast Care (Basel) 11 108-115

[7] Su M(2016)Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond[J] Ther Adv Med Oncol 8 360-374

[8] Huang CX(2016)Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC[J] Cancer Discov 6 F3-344

[9] Dai AP(2017)Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma[J] J Cancer 8 332-11446

[10] Brahmer JR(2007)Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation[J] Cancer Res 67 11438-120